Car T-Cell Therapy

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

Chimeric antigen receptor T cells are one of the newest immunotherapy options for multiple myeloma treatment.

In this episode, host Shikha Jain, MD, speaks with Christopher Heery, MD, of Arcellx, Inc. about making the transition from physician to chief medical officer, providing more access and education for clinical trials and more.

“With great power comes great responsibility.”

A phase 3 trial of ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma met its primary endpoint, according to the agent’s manufacturer.

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

A risk model based on low-pass whole-genome sequencing of cell-free DNA predicted which patients are more likely to respond to chimeric antigen receptor T-cell therapy for large B-cell lymphoma, study results showed.

NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.